osoz world
White Paper: Rethinking Digital Therapeutics’ Strategies The great momentum being generated by Digital Therapeutics (DTx) in North America and Europe is second to no other digital health segment today. Indeed, the ripple effects emanating from the German DiGA Framework are already being felt in Belgium, Spain, and Italy, with more countries to come. Furthermore, the addition of a €5.1B EUfinancial boost to accelerate digital innovation, and interoperability adoption makes Europe the new Digital Health Mecca for 2021 and beyond. However, with so much funding, innovation, and encouraging policies, the responsibility
46
OSOZ Polska 2/2021
is also to prove positive socio-economic impact and health outcomes.
Pit-Stop As DTx is still taking baby steps to higher maturity and adoption levels, it’s a good time for a pit-stop to reassess the
broader DTx context and redefine their strategic value proposition. The reality of clinical practice, and that of patients, is often made of intricate complexities which cannot be addressed by – let alone resolved through – a single or even an array of standalone DTx interventions. Indeed, patients with musculoskeletal (MSK), cardiovascular, metabolic, and other conditions often take painkillers and/or other disease-specific drugs. Moreover, because care delivery is still very often based on physicality, professional health services still are a cornerstone of any care plan today. In this context, although the benefits of some of the DTx interventions dealing
